Last reviewed · How we verify
NSC-CRAd-S-pk7
At a glance
| Generic name | NSC-CRAd-S-pk7 |
|---|---|
| Sponsor | Northwestern University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anemia
- Fatigue
- Lymphocyte count decreased
- Hypoalbuminemia
- Constipation
- Nausea
- Vomiting
- Platelet count decreased
- Thromboembolic event
- Sinus bradycardia
- Dyspepsia
- Gastrointestinal pain
Key clinical trials
- Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (PHASE1)
- Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma (PHASE1)
- Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NSC-CRAd-S-pk7 CI brief — competitive landscape report
- NSC-CRAd-S-pk7 updates RSS · CI watch RSS
- Northwestern University portfolio CI